ArticleEmerging infectious diseases2019
Hepatitis Rebound after Infection with Yellow Fever Virus.
Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Colombian protocol for the hospital management of non-critically ill patients with suspected or confirmed yellow fever.New microbes and new infections · 2026Review
- Yellow Fever, an Arboviral Disease with Public Health Impacts: General Aspects and the Use of the One Health Approach in the Context of This Zoonosis.Infection and drug resistance · 2026Review
- Article
- Risk factors associated with in-hospital mortality during yellow fever outbreak in Brazil.Frontiers in medicine · 2025Article
- Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.Microbiology spectrum · 2024Observational
- Yellow fever virus infection in human hepatocyte cells triggers an imbalance in redox homeostasis with increased reactive oxygen species production, oxidative stress, and decreased antioxidant enzymes.Free radical biology & medicine · 2024Article
- Characterization and Investigation of Risk Factors for Late-Relapsing Hepatitis After Yellow Fever.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Yellow Fever Molecular Diagnosis Using Urine Specimens during Acute and Convalescent Phases of the Disease.Journal of clinical microbiology · 2022Article
- Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds.International journal of molecular sciences · 2022Review
- Re-Emergence of Yellow Fever in Brazil during 2016-2019: Challenges, Lessons Learned, and Perspectives.Viruses · 2020Review
- Late-Relapsing Hepatitis after Yellow Fever.Viruses · 2020Article
- Recent sylvatic yellow fever virus transmission in Brazil: the news from an old disease.Virology journal · 2020Review
- Hepatitis Relapse after Yellow Fever Infection: Is There Another Wave?Revista da Sociedade Brasileira de Medicina Tropical · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2018, yellow fever with hepatitis was diagnosed for 2 unvaccinated travelers returning to France from Brazil. Hepatitis persisted for >6 months; liver enzyme levels again increased 2 months after disease onset with no detection of yellow fever virus RNA or other pathogens. Persistent hepatitis with hepatic cytolysis rebound probably resulted from immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.